Compare FG & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FG | ICUI |
|---|---|---|
| Founded | 1959 | 1984 |
| Country | United States | United States |
| Employees | 1173 | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | N/A | 1995 |
| Metric | FG | ICUI |
|---|---|---|
| Price | $26.75 | $137.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $31.00 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 638.2K | 254.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $7.94 | N/A |
| Revenue Next Year | $5.51 | $4.46 |
| P/E Ratio | ★ $8.41 | $118.68 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.57 | $107.02 |
| 52 Week High | $36.70 | $160.29 |
| Indicator | FG | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 54.56 |
| Support Level | $26.71 | $130.66 |
| Resistance Level | $29.84 | $142.31 |
| Average True Range (ATR) | 0.92 | 4.29 |
| MACD | -0.08 | 0.20 |
| Stochastic Oscillator | 28.34 | 51.57 |
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.